JOURNAL OF
THE INTERNATIONAL
AIDS SOCIETY

RESEARCH   **Open Access**

Activation and maturation of peripheral blood T cells in HIV-1-infected and HIV-1-uninfected adults in Burkina Faso: a cross-sectional study

Fabrice Tiba[1], Frans Nauwelaers[2], Lassana Sangaré[3], Boubacar Coulibaly[4], Hans-Georg Kräusslich[1†] and Thomas Böhler[1*†]

Abstract

Background: We wanted to explore to what extent environmental exposure to immune stimulants, which is expected to be more present in rural than in urban settings, influences T cell activation and maturation in healthy and in HIV-1-infected individuals in Burkina Faso in west Africa.

Methods: The proportion of circulating naïve T cells and the expression of the T cell activation markers, CD95 and CD38, were analyzed by immunophenotyping and three-colour flow cytometry in 63 healthy individuals and 137 treatment-naïve HIV-1-infected subjects from Ouagadougou (urban setting) and 26 healthy adults and 61 treatment-naïve patients from Nouna (rural).

Results: A slightly higher activation level of $CD4^+$ and $CD8^+$ peripheral blood T cells was seen in healthy adults living in Nouna than in those living in Ouagadougou. The percentages of naïve $CD45RA^{bright}$ $CCR7^+$ T cells were not significantly different between both study sites. Taking into consideration that relatively more HIV-1-infected patients in Nouna were in an advanced disease stage, no relevant differences were seen in T cell activation and maturation between patients at both study sites. As expected, the percentage of $CD95^+$ $CD4^+$ and $CD38^+$ $CD8^+$ T cells and the respective antigen density on these cells was significantly higher in patients than in controls in both settings. The percentage of naïve $CD8^+$ T cells was lower in HIV-1-infected subjects than in healthy controls irrespective of the study site, while a lower proportion of naïve $CD4^+$ T cells in patients compared with controls was seen only in Nouna.

Conclusions: Environmentally triggered immune activation may contribute to the increased expression of the activation markers CD95 and CD38 on peripheral blood T cells from healthy adults living in rural versus urban settings in Burkina Faso. T cell activation is further increased in HIV-1-infected individuals due to T cell loss and high plasma viral load levels. The observed variations in T cell activation levels or the proportion of naïve T cells in our study patients, however, are not explained by differences in $CD4^+$ T cell counts or HIV-1 plasma viral load levels alone.

Background

HIV pathogenesis is characterized by a progressive depletion of $CD4^+$ T cells in the course of the disease and a chronic systemic immune activation associated with a redistribution of T cell maturation phenotypes [1,2]. A similar activation status has been described in healthy individuals living in a tropical environment, albeit less pronounced compared with HIV-infected individuals [3-5]. Environmental stimuli, and in particular frequent intermittent infections, may be the driving force for such activation. They may thus play an important role in the HIV epidemic in Africa by accelerating $CD4^+$ T cell depletion, resulting in faster disease progression compared with the situation in developed countries [6-9].

* Correspondence: thomas.boehler@uni-heidelberg.de
† Contributed equally
[1]Department of Infectious Diseases, Virology, University of Heidelberg, Heidelberg, Germany
Full list of author information is available at the end of the article

BioMed Central

Previously, we had observed significant differences in the distribution of T cell maturation phenotypes between healthy adults in Burkina Faso [10] and published data from populations in Europe [11]. In the few studies that have addressed the immunological consequences of HIV-1-infection in Africans, the focus has been directed towards the expression of CD38 on CD8[+] T cells [12-14]. Upregulation of CD95 in HIV-infected subjects has been associated with disease progression in Europe [15-17], but has not yet been extensively studied in African patients. To increase our understanding of HIV-induced immune alteration in tropical settings, we concomitantly assessed the presence of naïve T cells and the activation level of T cells by expression of both CD95 and CD38 in HIV-1-infected adults, as well as in healthy controls, living in a rural or an urban setting in Burkina Faso. We wanted to explore to what extent environmental exposure to immune stimulants, which is expected to be more present in rural settings, influences T cell activation and maturation in healthy and in HIV-1-infected individuals.

Methods

Both the National Ethics Committee in Burkina Faso and the Institutional Ethics Committee of the University of Heidelberg approved this study. From May 2008 to September 2009, 137 treatment-naïve HIV-1-infected subjects without previous exposure to single or combined antiretroviral drugs or highly active antiretroviral combination therapy (HAART) who were visiting the outpatient clinic at the Centre Hôpitalier Universitaire Yalgado Ouedraogo (CHUYO) in Ouagadougou, the capital of Burkina Faso, were included (urban setting). In Nouna, 61 treatment-naïve adult patients were recruited at the Centre de la Recherche en Santé de Nouna (CRSN) from January 2009 to September 2009 (rural setting).

All subjects signed an informed consent form prior to entering the study. Fresh blood samples, clinical and socio-demographic data were collected from the patients at regular clinical visits. For comparison of T cell maturation and activation markers between HIV-1-infected patients and control subjects living in urban and rural Burkina Faso, healthy adults were recruited from clinical and laboratory personnel at the CHUYO in Ouagadougou (urban, n = 63) and at the CRSN in Nouna (rural, n = 26).

At both study sites, patients and controls were always tested simultaneously during six periods of six to eight weeks each at approximately three-month intervals. In order to minimize preanalytic confounders, venipuncture, blood staining and fluorescence-activated cell sorting (FACS) analyses were done in the same laboratory in the respective study sites. Storage time never

exceeded four hours. Fifty microliters of peripheral blood anticoagulated with K_3-EDTA were used to determine absolute numbers of CD4[+] and CD8[+] T cells in the FACSCount system (BD Biosciences, San Jose, CA, USA) according to the manufacturer's instructions. Plasma obtained from 125 patients in Ouagadougou and 61 patients in Nouna was used for the quantification of viral particles with the Abbott m2000rt RealTime HIV-1 test (Abbott, Chicago, IL, USA) at the Laboratory of Bacteriology and Virology of CHUYO after short centrifugation of 5ml whole blood at 3000rpm. The detection limit was 50 HIV-1 RNA copies per ml of plasma.

Multiparametric flow cytometry was performed using a three-colour FACSCalibur flow cytometer (FCM) in Ouagadougou and a FACScan FCM in Nouna (both from BD Biosciences). Measurements were done with cocktails of fluorochrome-labelled monoclonal antibodies (all from BD Biosciences) aliquoted in 3ml BD FACS tubes and 100 μl venous whole blood anticoagulated with K_3-EDTA exactly as specified by the manufacturer. CaliBrite beads (BD Biosciences) were used to set the instrument on a regular basis. Instrument settings were controlled longitudinally and remained constant during the study. Data acquisition for each analysis was stopped manually when at least 10,000 events were counted in the predefined gate. List mode data from all samples were analyzed using the CellQuest Pro software, version 5.2 (BD Biosciences).

CD4[+] and CD8[+] naïve and memory T cell subsets were assessed with anti-CD4 or anti-CD8-PerCP, anti-CD45RA-FITC and anti-CCR7-PE conjugated monoclonal antibodies as described [10]. Naïve T cells were identified as CD45RA[bright] CCR7[+] CD4[+] or CD8[bright] lymphocytes [18-20]. T cell activation was determined with anti-CD95-PE, anti-CD3-PerCP and anti-CD4-FITC to assess the expression of CD95 on CD4[+] T cells, and anti-CD38-PE, anti-CD3-PerCP and anti-CD8-FITC to assess the expression of CD38 on CD8[+] T cells. Figure 1A to 1D shows typical examples of flow-cytometric assessment of the percentage of naïve and activated T cell subpopulations.

The median fluorescence intensity (MFI) of CD95 on CD4[+] T cells is characterized by a bimodal distribution with two peaks, i.e., CD95[dim] and CD95[bright] [15,21,22] which were analyzed separately. We had shown in the past by magnetic bead isolation and three-colour flow cytometry [10] and by four-colour flow cytometry [21] that the cell populations constituting the CD95[dim] and the CD95[bright] peak correspond to resting naïve and activated memory cells, respectively. CD4[+] T cells classified as "naïve", "resting", or "not activated" by surface marker analysis using, for example, CD45RA, CD45R0, CD62L or CCR7, may thus express various levels of the activation marker CD95. The expression of CD38 on

Figure 1 Flow-cytometric assessment of the percentage of naïve T cells and the expression of T cell activation markers. For the determination of naïve T cell frequencies, whole blood was stained with anti-CD4 or -CD8 together with anti-CCR7 and anti-CD45RA antibodies. Panels A and B show dot plots of CD4+ and CD8+ T cells with their respective gating of the frequencies of naïve cells as shown in the region markers. For the determination of activated T cell frequencies, whole blood was stained with anti-CD3 and anti-CD4 or anti-CD8 together with anti-CD95 or anti-CD38 antibodies, respectively. Panels C and D show histogram plots of CD4+ and CD8+ T cells expressing CD95 and CD38 activation markers, respectively. The peak of unstained control is shown in the first decade of each plot. Peaks of CD95dim and CD95bright on CD4+ cell populations were separately analyzed. The expression of CD38 on CD8+ T cells was characterized by a unique peak.

CD8+ T cells is characterized by a skewed unimodal histogram curve [23,24]; the cursor for MFI determination was set on CD38+ cells. The QuantiBrite test kit (BD Biosciences) was used in all experiments to convert MFI values into antibody-binding capacity (ABC) per cell according to the instructions of the manufacturer. Since calibration curves were generated on each instrument at each site separately using the same batch of QuantiBrite beads, the resulting numerical ABC values were not influenced by the different FCM settings at the different study sites.

Mean values and standard deviations, as well as median values and percentiles, were calculated for each variable using the GraphPad Prism version 5.00 (Graph Pad Inc., San Diego, California, USA). Differences between healthy controls and HIV-1-infected subjects, as well as differences between the different study sites, were analyzed using the non-parametric Mann-Whitney U-test, p

values < 0.01 indicated statistical significance. Correlations between T cell activation levels and $CD4^+$ T cell counts or HIV-1 plasma viral load were explored separately in the patient cohorts from Nouna and Ouagadougou by linear regression analysis using Pearson's correlation coefficients (r) and the coefficients of determination (R^2).

Results

Differences between healthy controls living in rural and urban settings

Table 1 shows detailed information on the number, age and gender distribution of HIV-1-infected patients and healthy controls at both study sites. The number of patients with complete multiparameter flow-cytometric measurements varied slightly for each test because the necessary monoclonal antibodies were not always available due to logistic delivery problems in Burkina Faso (exact numbers are given in additional file 1). Healthy adults living in the rural setting showed a higher percentage of $CD95^+$ $CD4^+$ T cells in peripheral blood than the controls in the urban setting (median [10th and 90th percentile]: 91 [77-98] % in Nouna vs. 82 [68-95]% in Ouagadougou, p < 0.01; see also additional file 1).

The percentage of $CD38^+$ $CD8^+$ T cells was higher in Nouna (83 [63-98]%) than in Ouagadougou (63 [36-83]%; p < 0.0001) and also the expression level (ABC) of CD95 on $CD95^{dim}$ $CD4^+$ T cells and of CD38 on $CD38^+$ $CD8^+$ T cells was significantly higher in Nouna (additional file 1). The percentages of naïve $CD45RA^{bright}$ $CCR7^+$ $CD4^+$ and $CD8^+$ T cells were not significantly different between both study sites. However, there was a

moderate but significant correlation between the percentage of $CD95^+$ $CD4^+$ T cells and the percentage of naïve $CD4^+$ T cells in healthy adults from Ouagadougou and a tendency towards a similar correlation in the Nouna controls (additional file 2). No such relationship was seen between the percentage of $CD38^+$ $CD8^+$ T cells and naïve $CD8^+$ T cells (data not shown).

In Ouagadougou controls, the percentage of naïve $CD8^+$ T cells decreased slightly but significantly with increasing age (additional file 3). This correlation did not reach statistical significance in healthy adults living in the rural setting (Nouna), probably because of the lower number of observations in Nouna compared with Ouagadougou (Table 1). In healthy adults from both settings, the percentage of naïve $CD4^+$ T cells showed a slight but statistically not significant trend to decrease with increasing age (additional file 3). In healthy controls, neither the percentages of activated $CD95^+$ or $CD38^+$ T cells, nor the ABC values of CD95 or CD38, were significantly correlated with age (data not shown). In addition, no significant gender-related differences in the immunologic parameters tested were seen (additional files 4 and 5).

Differences between HIV-1-infected individuals in rural and urban settings

As shown in Table 1, patients in the rural setting of Nouna had significantly lower $CD4^+$ T cell counts and slightly higher HIV-1 plasma viral load levels compared with patients in the city of Ouagadougou. Relatively more patients in Nouna were in an advanced disease stage (immunologic class C according to the 1993

Table 1 Comparison of clinical and immunological parameters between HIV-1-infected and healthy adults living in Burkina Faso

	Nouna (rural)		p	Ouagadougou (urban)		p
	Patients	**Controls**		**Patients**	**Controls**	
n =	61	26	-	137	63	-
Female [n = ; (%)]	44 (72%)	16 (61%)	<0.0001	98 (72%)[c]	25 (40%)*	<0.0001
Age [years; median, range]	35 (30-43)	27 (19-35)	<0.0001	35 (23-48)	28 (20-35)	<0.0001
HIV-1 plasma viral load (log_{10} copies ml^{-1})	5.8 (4.6-6.6) [n = 61]	n.d.	-	5.4 (4.0-6.2)[b] [n = 125]	n.d.	-
$CD4^+$ T cell count [μl^{-1}]	174 (33-314)	n.d.	-	256 (118-387)[b]	n.d.	-
CDC-stage A [n = ; (%)]	01 (02%)	n.d.	-	22 (16%)[c]	n.d.	-
CDC-stage B [n = ; (%)]	23 (38%)	n.d.	-	55 (40%)[c]	n.d.	-
CDC-stage C [n = ; (%)]	37 (60%)	n.d.	-	60 (44%)[c]	n.d.	-

All patients were "treatment-naïve", i.e., without known or reported previous exposure to single or combined antiretroviral drugs or highly active antiretroviral combination therapy (HAART). If not otherwise indicated, median values are shown with 10th and 90th percentiles in parentheses. The Mann-Whitney U-test was used to compare patients and controls in the rural and urban setting, as well as patients in the rural and urban setting and controls in the rural and the urban setting separately.

Abbreviations: p - p value for the difference between patients and controls; CDC - Centers of Disease Control and Prevention immunologic staging; n.d. - not done

[a]p <0.05, [b]p <0.001, [c]p <0.001 indicating statistically significant differences between HIV-1 infected subjects in Ouagadougou (urban) and HIV-1 infected subjects from Nouna (rural)

*p < 0.05; **p < 0.01; ***p < 0.001, indicating statistically significant differences between healthy controls in Ouagadougou (urban) and healthy controls in Nouna (rural)

classification of the Centers of Disease Control [25]). Consequently, the percentage of circulating naïve T cells was lower in patients living in Nouna compared with those living in Ouagadougou (Figure 2, additional file 1). This difference was statistically significant only for CD4$^+$ T cells and was detectable also in patients with similar CD4$^+$ T cell counts or patients with comparable HIV-1 plasma viral load levels (additional file 6).

When patients with CD4$^+$ T cell counts between 200 and 400 cells/mm^3 or patients with HIV-1 plasma viral load levels in the range of 4 to 6 log$_{10}$ RNA copies per ml were compared, a slightly but significantly lower anti-CD95 antibody binding capacity (ABC) of CD95^{dim} CD4$^+$ T cells was observed in patients from Nouna

compared with patients from Ouagadogou (additional file 7). In patients with HIV-1 plasma viral load levels in the range of 4 to 6 log$_{10}$ RNA copies per ml, the expression level (ABC) of CD38 on CD38$^+$ CD8$^+$ T cells was slightly higher in the rural than in the urban setting. No significant difference between patients at both study sites was seen regarding ABC of CD95^{bright} CD4$^+$ T cells (additional file 7).

Differences between HIV-1-infected patients and healthy controls

Irrespective of the rural or urban setting the percentage of CD95$^+$ CD4$^+$ and CD38$^+$ CD8$^+$ T cells was significantly higher and the percentage of naïve CD8$^+$ T cells

Figure 2 Percentage of naïve and activated CD4$^+$ and CD8$^+$ T cells in patients and healthy controls. Whisker plots were used to compare the percentages of naïve and activated CD4$^+$ and CD8$^+$ T cells between HIV-1 infected subjects and healthy controls from the different study sites using the Mann-Whitney U-test. Panels A and B show the comparison of the percentage of naïve CD4$^+$ and CD8$^+$ T cells, respectively, between HIV-1 infected subjects and healthy controls from Nouna (rural) and Ouagadougou (urban). Panels C and D show the comparison of the percentage of CD95$^+$CD4$^+$ and of CD38$^+$CD8$^+$ T cells, respectively, between HIV-1 infected subjects and healthy controls from Nouna and Ouagadougou. Symbols: (^{a}) indicates a statistically significant difference (p < 0.05) between HIV-1 infected subjects in Ouagadougou and HIV-1 infected subjects from Nouna; (** or ***) indicates a statistically significant difference (p < 0.001 and p < 0.0001) between healthy controls in Ouagadougou and healthy controls in Nouna.

was lower in patients compared to healthy controls (Figure 2, additional file 1). The percentage of naïve CD4[+] T cells was significantly lower in HIV-1-infected subjects compared to healthy controls in Nouna but not in Ouagadougou (Figure 2, additional file 1). Anti-CD95 antibody binding capacity (ABC) of CD95[dim] and CD95[bright] CD4[+] T cells as well as CD38 ABC of CD38[+] CD8[+] T cells was elevated in patients from both study sites compared to their respective controls (Figure 3, additional file 1).

Determinants of T cell activation in HIV-1-infected patients

In HIV-1-infected patients living in Ouagadougou, the percentage of CD95[+] CD4[+] T cells was negatively correlated with CD4[+] T cell counts ($r = -0.526$, $R^2 = 0.277$, $p < 0.0001$) and positively correlated with HIV-1 plasma viral load levels ($r = 0.434$, $R^2 = 0.188$, $p < 0.0001$; additional file 8). In the Nouna patient cohort, a similar relationship between the percentage of CD95[+] CD4[+] T cells and CD4[+] T cell counts was seen ($r = -0.512$, $R^2 = 0.263$, $p = 0.0001$) but there was no correlation between CD95[+] CD4[+] T cells and HIV-1-plasma viral load levels (additional file 8). The percentage of naïve CD45RA[+] CCR7[+] CD4[+] T cells showed a moderate positive correlation with CD4[+] T cell counts (statistically significant only in the Ouagadougou cohort) and no clear correlation with HIV-1-plasma viral load levels (additional file 8).

In patients from Ouagadougou, anti-CD95 antibody binding capacity (ABC) of CD95[bright] CD4[+] T cells was


Figure 3 Expression of T cell activation markers on CD4[+] and CD8[+] T cells in patients and healthy controls. Whisker plots were used to compare the antibody-binding capacity (ABC) of CD95[+] CD4[+] T cells (panel A and B) and CD38[+] CD8[+] T cells (panel C) between HIV-1 infected subjects and healthy controls from the different study sites using the Mann-Whitney U-test. Panel A shows data on the ABC of CD95[dim] CD4[+] CD3[+] cells, panel B on the ABC of CD95[bright]CD4[+] CD3[+] cells, and panel C shows the comparison of the ABC of CD38[+] CD8[+] CD3[+] cells between HIV-1 infected subjects and healthy controls from Nouna (rural) and Ouagadougou (urban). Symbols: (*) indicates statistically significant difference ($p < 0.05$) between healthy controls in Ouagadougou (urban) and healthy controls in Nouna (rural).

Figure 4 T cell activation, CD4[+] T cell counts, and HIV-1 plasma viral load in the urban setting. Correlation between activation marker antibody binding capacity (ABC) of peripheral blood T cells and CD4[+] T cell counts in 132 treatment-naïve HIV-1 infected patients (panels A, C and E) as well as HIV-1 plasma viral load levels in 125 patients (panels B, D and F) living in Ouagadougou, the capital of Burkina Faso. ABC was derived from the median fluorescence intensity as described in the Methods section. Panel A shows the correlation between the ABC of CD4[+]CD95[bright] T cells and CD4[+] T cell counts, panel B between the ABC of CD4[+]CD95[bright] T cells and HIV-1 plasma viral load. Panel C depicts the correlation between the ABC of CD4[+]CD95[dim] T cells and CD4[+] T cell counts, and panel D the correlation between the ABC of CD4[+]CD95[dim] T cells and HIV-1 plasma viral load. Panel E shows the correlation between the ABC of CD8[+]CD38[+] T cells and CD4[+] T cell counts, and panel F between the ABC of CD8[+]CD38[+] T cells and HIV-1 plasma viral load. Correlations between variables were explored by calculation of Pearson's correlation coefficient (r) and the coefficient of determination (R^2), which are indicated for each analysis.

moderately negatively correlated with CD4[+] T cell counts (Figure 4A) and positively with HIV-1 plasma viral load levels (Figure 4B). In the Nouna patient cohort, the negative correlation between anti-CD95 ABC of CD95[bright] CD4[+] T cells and CD4[+] T cell counts (Figure 5A) was weak and not statistically significant, whereas the relationship with HIV-1 plasma viral load levels was similar to the one seen in patients from Ouagadougou (Figure 5B). Anti-CD95 ABC of CD95[dim] CD4[+] T cells was moderately negatively correlated with CD4[+] T cell counts (Figure 4C and 5C), but the level of statistical significance was reached only in patients from Ouagadougou and not from Nouna. In patients from both study sites, anti-CD95 ABC of CD95[dim] CD4[+] T cells showed a somewhat stronger and statistically significant positive correlation with HIV-1 plasma viral load levels (Figure 4D and 5D).

In the CD8[+] T cell compartment of the patients from Ouagadougou, the percentage of CD38[+] CD8[+] T cells was moderately negatively correlated with CD4[+] T cell counts (r = -0.365, R^2 = 0.133, p < 0.0001) and

positively with HIV-1 plasma viral load levels (r = 0.452, R^2 = 0.204, p < 0.0001; additional file 8). In the Nouna patient cohort, similar relationships were seen, but did not always reach the level of statistical significance (additional file 8). Anti-CD38 ABC of CD38[+] CD8[+] T cells showed a significant negative correlation with CD4[+] T cell counts in both patient cohorts (Figures 4E and 5E). The positive correlation of anti-CD38 ABC with HIV-1 plasma viral load levels was statistically significant in patients from Ouagadougou (Figure 4F), but not in patients from Nouna (Figure 5F).

Discussion

Our study reveals that environmental exposure to immune stimulants, which is expected to be more present in rural than in urban settings, influences peripheral blood T cell activation in healthy individuals and in HIV-1-infected patients in west Africa. Healthy adults in Nouna (rural setting) showed a higher percentage of CD95[+] CD4[+] T cells and an elevated expression level (antibody-binding capacity, ABC) of CD95 on CD95[dim]

Figure 5 T cell activation, CD4+ T cell counts, and HIV-1 plasma viral load in the rural setting. Correlation between activation marker antibody binding capacity (ABC) of peripheral blood T cells and CD4+ T cell counts (panels A, C and E), or HIV-1 plasma viral load levels (panels B, D and F) in 61 treatment-naïve HIV-1 infected patients living in Nouna, rural Burkina Faso. ABC was derived from the median fluorescence intensity as described in the Methods section. Panel A shows the correlation between the ABC of CD4+CD95bright T cells and CD4+ T cell counts, and panel B between the ABC of CD4+CD95bright T cells and HIV-1 plasma viral load. Panel C depicts the correlation between the ABC of CD4+CD95dim T cells and CD4+ T cell counts, and panel D the correlation between the ABC of CD4+CD95dim T cells and HIV-1 plasma viral load. Panel E shows the correlation between the ABC of CD8+CD38+ T cells and CD4+ T cell counts, and panel F between the ABC of CD8+CD38+ T cells and HIV-1 plasma viral load. Correlations between variables were explored by calculation of Pearson's correlation coefficient (r) and the coefficient of determination (R^2), which are indicated for each analysis.

CD4+ T cells in peripheral blood compared with healthy adults in Ouagadougou (urban setting). The percentage of CD38+ CD8+ T cells was also higher and the expression of CD38 on CD38+ CD8+ T cells was increased. Thus, healthy adults living in the rural setting harbour more peripheral blood T cells showing signs of cellular activation compared with individuals living in the urban setting.

Both the expression of activation markers and the distribution pattern of T cell maturation phenotypes may be a surrogate parameter for environmentally driven immuno-senescence [11,26,27]. A previous study from Ethiopia has shown comparable CD4+ T cell counts but higher CD8+ T cell counts in healthy male subjects living in Akaki (urban) and Wonji (rural). In this setting, both the proportions of activated CD38+ peripheral blood T cells and of naïve CD45RA+ CD27+ T cells were similar [27].

In our own study, differences in T cell activation between the rural and the urban populations were not accompanied by significant differences in patterns of peripheral T cell maturation. The percentages of naïve

CD4+ and CD8+ T cells were not significantly higher in healthy adults living in Ouagadougou than in those living in Nouna. The percentage of activated CD95+ CD4+ T cells was negatively correlated with the percentage of naïve CD4+ T cells (additional file 2). No such correlation was seen between naïve and activated CD8+ T cells (data not shown). Yet the linear decrease in the proportion of naïve T cells with increasing age as described for Europeans [11] seems to be present also in the west African population studied by us (additional file 3). Neither the expression of CD95+ on CD4+ T cells, nor of CD38+ on CD8+ T cells, was significantly correlated with age (data not shown). In contrast to published observations from Dakar, Senegal [28], we did not see a significant gender-related difference in T cell activation or maturation in our study populations (additional files 4 and 5).

In our study, the observed increase in CD95+ T cells in healthy adults living in Nouna compared with individuals living in Ouagadougou was not caused by a reduction in the proportion of CD95dim naïve CD4+ T cells, but involved changes in CD95 receptor density on the

naïve cell population. T cell surface markers like CD95 on CD4[+] and CD38 on CD8[+] T cells seem to be more sensitive than the T cell maturation phenotypes towards the mechanisms that mediate environmental influences on the human peripheral blood T cell pool. We had observed high prevalences of herpes viruses, dengue and hepatitis B virus in the study area [29], and had seen specific CD4[+] T cell responses against Plasmodium falciparum in 14 out of 17 healthy adults in Nouna (data not shown). T cell responses to viral infection would be expected to increase predominantly the expression of CD38 on CD8[+] T cells [30]. In contrast, CD4[+] T cell responses to Plasmodium falciparum may increase the expression of CD95 on resting naïve cells by unspecific "bystander" activation due to an increased production of interferon gamma [31].

One could thus hypothesize that circulating naïve T cells in healthy adults living in the rural setting may become constitutively CD95[+] in response to environmental stimuli. It is not known whether increased CD95 expression on these cells is also increasing the sensitivity for CD95-induced apoptosis or altering other functional T cell properties. The CD95 signalling cascade has pleiotropic effects on peripheral blood T cells. While high signal intensities may silence T cell receptor-induced activation (thus inducing T cell anergy) or may cause activation-induced cell death via apoptosis, low signal intensities especially in resting T cells may exert co-stimulatory effects [32]. An increase in the expression level of CD95 on CD4[+] lymphocytes may therefore lower the general activation threshold of resting naïve CD4[+] T cells.

Are environmental factors acting in a similar way in HIV-1-infected adults? There was no relevant and statistically significant difference in the level of T cell activation and T cell maturation between patients from both study sites. Relatively more patients living in the rural setting of Nouna were in an advanced disease stage. The small but significant difference in the percentage of CD45RA[+] CCR7[+] naïve CD4[+] lymphocytes between patients living in the two settings is best explained by this fact. When patients with HIV-1 plasma viral load levels of 4 to 6 $\log_{10}$ RNA copies per ml at both study sites were compared, the expression level of CD38 on CD8[+] T cells was slightly higher in the rural than in the urban setting. In the CD8[+] T cell compartment, environmental influences may therefore add to HIV-induced changes of the activation status.

Patients with comparable CD4[+] T cell counts (200 to 400 cells/mm^3) or HIV-1 plasma viral load levels (4 to 6 $\log_{10}$ RNA copies per ml) in the rural setting showed lower percentages of naïve CD4[+] T cells than those in the urban setting with similar disease activity. These observations indicate that environmental determinants

of T cell activation may act also in the CD4[+] T cell compartment of HIV-1-infected patients living in the rural setting.

Anti-CD95 ABC of CD95[dim] CD4[+] T cells were slightly lower in the Nouna patient cohort than in patients from Ouagadougou. It is tempting to speculate that, due to environmental trigger mechanisms, CD95[dim] naïve CD4[+] T cells in HIV-1-infected individuals living in the rural setting are more prone to get activated or to undergo programmed cell death (apoptosis) upon low level CD95 triggering than in patients who live in an urban environment. These cells may then either be lost due to an increased susceptibility for CD95-induced apoptosis, which is a known feature of peripheral blood T cells in HIV-1-infected patients [15], or due to accelerated maturation.

We were not able to incorporate simultaneous T cell phenotyping and assessment of T cell function into our study protocol. However, elevated immune activation, together with increased expression of CD95 and increased spontaneous T cell apoptosis, has been described in a cohort of healthy women from Nairobi, Kenya [26], as well as in healthy adults from Ghana [33]. Such investigations should be included in future studies in order to clarify the functional capacity of CD95[dim] naïve CD4[+] T cells both in HIV-1-infected individuals and in healthy controls living under different environmental conditions.

Infection with HIV-1, however, exerts a much stronger effect on T cell activation than any differences in environmental conditions. Our results confirm the well-known finding that peripheral blood T cells of HIV-1-infected patients show a higher expression of activation markers compared with healthy controls of similar age [3-5]. The percentage of CD95[+] CD4[+] and CD38[+] CD8[+] T cells, anti-CD95 ABC of CD95[dim] and CD95[bright] CD4[+] T cells and CD38 ABC of CD38[+] CD8[+] T cells were all elevated in patients compared with controls at both study sites. This observation was not accompanied by similar changes in the expression of T cell maturation markers. Only in Nouna the percentage of naïve CD4[+] T cells was significantly lower in HIV-1-infected subjects than in healthy controls. A possible explanation for this observation may be the aforementioned (hypothetical) CD95-mediated loss of CD95[dim] naïve CD4[+] T cells in HIV-1-infected individuals living in the rural setting. The difference in age between patients and controls does not explain the observed differences in the percentage of naïve T cells.

Absolute numbers of naïve CD4[+] T cells in HIV-1-infected subjects (mean±standard deviation: 32.5 ± 33.6 cells/mm^3 in Nouna, 72.3 ± 79.3 cells/mm^3 in Ouagadougou) were significantly lower than the population-specific reference range in our study area (5th to 95th

percentile: 35 to 496 cells/mm^3) [10]. In the CD8$^+$ T cell compartment, the proportion of naïve lymphocytes was significantly reduced in HIV-1-infected patients compared with healthy controls at both study sites. The absolute counts of naïve CD8$^+$ T cells (mean±standard deviation: 43.0 ± 49.4 cells/mm^3 in Nouna; 53.0 ± 61.6 cells/mm^3 in Ouagadougou) were significantly lower than those described for healthy adults in our study area (5th to 95th percentile: 36 to 363 cells/mm^3) [10].

Chronic immune activation observed in HIV-1-infected subjects has been shown to be associated both with low CD4$^+$ T cell counts and high HIV-1 RNA levels [23,34]. CD38, the most extensively studied activation marker in HIV-1-infected subjects, had been reported to be upregulated on CD8$^+$ T cells in association with disease progression [12-14,35-38]. The degree of correlation between CD38 expression on CD8$^+$ T cells and HIV-1 plasma viral load in our study was moderate but comparable to other African studies [12,14].

Upregulation of the T cell activation marker CD95 on CD4$^+$ had previously been reported on CD4$^+$ T cells of HIV-1 infected subjects in industrialized countries and was also associated with disease progression [15,17,21,39]. The small but significant increase of CD95 ABC of both CD95^{dim} and CD95^{bright} CD4$^+$ T cells with increasing viral load indicates that CD95 expression in HIV-1 infected patients may be partially driven by viral replication. Circulating CD95$^+$ CD4$^+$ T cells in patients with advanced disease are mainly CD95^{bright} memory cells, and disappearance of CD95^{dim} T cells in these patients usually parallels the depletion of CD45RA^{bright} CCR7$^+$ naïve T lymphocytes [21].

In HIV-1-infected subjects living in Burkina Faso, T cell activation levels increased and proportions of naïve T cells decreased both with increasing HIV-1 plasma viral load and decreasing CD4$^+$ T cell counts. A significant correlation (r = -0.456, R^2 = 0.19, p < 0.0001; data not shown) was also observed between absolute CD4$^+$ T cell counts and HIV-1 plasma viral load levels in Ouagadougou. However, no causal relationship can be inferred from our data between these parameters and changes in T cell activation and maturation patterns in HIV-1-infected patients. Skewed maturation and increased activation of peripheral blood T cells in HIV-1-infected patients compared with healthy controls may be explained by HIV-induced T cell loss. This may lead to peripheral homeostatic expansion causing an increase in the expression levels of CD95 or CD38 on circulating naïve T cells as a sign of cellular cycling [40]. Differences in the exposure to other viral infections than HIV is an unlikely cause of the deviations observed in the CD4$^+$ and CD8$^+$ T cell compartments in these individuals. HIV replication acts as a continuous T cell stimulus, but is expected to increase primarily the expression of CD38 on CD8$^+$ T cells [35].

These observations point to a common problem in flow cytometric analysis of T cell activation markers in HIV-infected individuals. In the individual patient with a high CD4$^+$ T cell count, an elevated expression of CD95 on CD95^{dim} CD4$^+$ T cells and of CD38 on CD38$^+$ CD8$^+$ T cells most probably indicates a high HIV-1 plasma viral load. In the lymphopenic patient with advanced disease and a low CD4$^+$ T cell count, phenotypic effects of cell cycling due to homeostatic autoproliferation may influence the expression levels of these molecular markers of T cell activation.

Conclusions

We conclude from our data that environmentally triggered immune activation contributes to the increased expression of the T cell activation markers, CD95 and CD38, on peripheral blood T cells from healthy adults living in rural versus urban settings in Burkina Faso. Environmentally induced T cell activation is also detectable in HIV-1-infected individuals, albeit at a much lower level than the changes caused by high HIV-1 plasma viral load and/or HIV-induced T cell loss. The observed variations in T cell activation levels and the proportion of naïve T cells in our study patients, however, are not explained by differences in CD4$^+$ T cell counts and HIV-1 plasma viral load levels alone. At least under the given environmental conditions in west Africa, where people are continuously exposed to T cell stimulating agents, such as viral antigens or parasite infestations [29,41-46], the clinical value of additional measurements of these immune markers in HIV-1-infected patients remains to be demonstrated.

Additional material

Additional file 1: Supplementary material a (MS Word). Comparison of clinical and immunological parameters between HIV-1-infected and healthy adults living in rural and urban Burkina Faso.

Additional file 2: Supplementary material b (MS PowerPoint). Correlation between the percentage of activated T cells and the percentage of naïve T cells in healthy adults in Nouna and Ouagadougou.

Additional file 3: Supplementary material c (MS PowerPoint). Correlation between the percentage of naïve T cells and age in healthy adults in Nouna and Ouagadougou.

Additional file 4: Supplementary material d (MS PowerPoint). Gender-related differences in the percentage of naïve and activated T cells or expression levels of T cell activation markers in healthy adults living in Nouna.

Additional file 5: Supplementary material e (MS PowerPoint). Gender-related differences in the percentage of naïve and activated T cells or expression levels of T cell activation markers in healthy adults living in Ouagadougou.

Author details
[1]Department of Infectious Diseases, Virology, University of Heidelberg,
Heidelberg, Germany. [2]BD Biosciences, Erembodegem, Belgium. [3]Centre
Hospitalier Universitaire Yalgado Ouedraogo, Ouagadougou, Burkina Faso.
[4]Centre de Recherche en Santé de Nouna, Nouna, Burkina Faso.

Authors' contributions
FT organized recruitment of patients and healthy controls in Nouna and
Ouagadougou, collected clinical and laboratory data, performed
immunological and virological measurements in the laboratories of the
CRSN and CHUYO with the help of LS and BC, and wrote the first draft of
the manuscript. TB, FN and HGK designed the study, evaluated interim
findings, and assisted in revising subsequent versions of the manuscript. All
authors have read and approved the final version of this manuscript.

Competing interests
The authors declare that they have no competing interests.

References
1. Barbour JD, Ndhlovu LC, Xuan Tan Q, Ho T, Epling L, Bredt BM, Levy JA,
   Hecht FM, Sinclair E: **High CD8+ T cell activation marks a less
   differentiated HIV-1 specific CD8+ T cell response that is not altered by
   suppression of viral replication.** *PLoS One* 2009, **4**:e4408.
2. Burgers WA, Riou C, Mlotshwa M, Maenetje P, de Assis Rosa D, Brenchley J,
   Mlisana K, Douek DC, Koup R, Roederer M, de Bruyn G, Karim SA,
   Williamson C, Gray CM, the CAPRISA 002 Acute Infection Study Team:
   **Association of HIV-specific and total CD8+ T memory phenotypes in
   subtype C HIV-1 infection with viral set point.** *J Immunol* 2009,
   182:4751-4761.
3. Clerici M, Butto S, Lukwiya M, Saresella M, Declich S, Trabattoni D, Pastori C,
   Piconi S, Fracasso C, Fabiani M, Ferrante P, Rizzardini G, Lopalco L: **Immune
   activation in africa is environmentally-driven and is associated with
   upregulation of CCR5. Italian-Ugandan AIDS Project.** *AIDS* 2000,
   14:2083-2092.
4. Begaud E, Chartier L, Marechal V, Ipero J, Leal J, Versmisse P, Breton G,
   Fontanet A, Capoulade-Metay C, Fleury H, Barré-Sinoussi F, Scott-Algara D,
   Pancino G: **Reduced CD4 T cell activation and in vitro susceptibility to
   HIV-1 infection in exposed uninfected Central Africans.** *Retrovirology* 2006,
   3:35.
5. Hazenberg MD, Otto SA, Hamann D, Roos MT, Schuitemaker H, de Boer RJ,
   Miedema F: **Depletion of naive CD4 T cells by CXCR4-using HIV-1
   variants occurs mainly through increased T-cell death and activation.**
   AIDS 2003, **17**:1419-1424.
6. Bentwich Z, Kalinkovich A, Weisman Z: **Immune activation is a dominant
   factor in the pathogenesis of African AIDS.** *Immunol Today* 1995,
   16:187-191.
7. Del Amo J, Petruckevitch A, Phillips A, Johnson AM, Stephenson J,
   Desmond N, Hanscheid T, Low N, Newell A, Obasi A, Paine K, Pym A,
   Theodore CM, De Cock KM: **Disease progression and survival in HIV-1-
   infected Africans in London.** *AIDS* 1998, **12**:1203-1209.
8. Low N, Paine K, Clark R, Mahalingam M, Pozniak AL: **AIDS survival and
   progression in black Africans living in south London, 1986-1994.**
   Genitourin Med 1996, **72**:12-16.
9. Lester RT, Jaoko W, Plummer FA, Kaul R: **Sex, microbial translocation, and
   the African HIV epidemic.** *Proc Natl Acad Sci USA* 2009, **106**:E89, author
   reply E90.
10. Böhler T, von Au M, Klose N, Müller K, Coulibaly B, Nauwelaers F,
    Spengler HP, Kynast-Wolf G, Kräusslich HG: **Evaluation of a simplified dual-
    platform flow cytometric method for measurement of lymphocyte
    subsets and T-cell maturation phenotypes in the population of Nouna,
    Burkina Faso.** *Clin Vaccine Immunol* 2007, **14**:775-781.
11. Saule P, Trauet J, Dutriez V, Lekeux V, Dessaint JP, Labalette M:
    **Accumulation of memory T cells from childhood to old age: central and
    effector memory cells in CD4(+) versus effector memory and terminally
    differentiated memory cells in CD8(+) compartment.** *Mech Ageing Dev*
    2006, **127**:274-281.
12. Ondoa P, Koblavi-Deme S, Borget MY, Nolan ML, Nkengasong JN, Kestens L:
    **Assessment of CD8 T cell immune activation markers to monitor
    response to antiretroviral therapy among HIV-1 infected patients in Cote
    d'Ivoire.** *Clin Exp Immunol* 2005, **140**:138-148.
13. Koblavi-Deme S, Maran M, Kabran N, Borget MY, Kalou M, Kestens L,
    Maurice C, Sassan-Morokro M, Ekpini ER, Roels TH, Chorba T,
    Nkengasong JN: **Changes in levels of immune activation and
    reconstitution markers among HIV-1-infected Africans receiving
    antiretroviral therapy.** *AIDS* 2003, **17(Suppl 3)**:S17-22.
14. Glencross DK, Janossy G, Coetzee LM, Lawrie D, Scott LE, Sanne I,
    McIntyre JA, Stevens W: **CD8/CD38 activation yields important clinical
    information of effective antiretroviral therapy: findings from the first
    year of the CIPRA-SA cohort.** *Cytometry B Clin Cytom* 2008, **74(Suppl 1)**:
    S131-140.
15. Böhler T, Bäumler C, Herr I, Groll A, Kurz M, Debatin KM: **Activation of the
    CD95 system increases with disease progression in human
    immunodeficiency virus type 1-infected children and adolescents.** *Pediatr
    Infect Dis J* 1997, **16**:754-759.
16. Böhler T, Debatin KM, Wintergerst U: **T-cell apoptosis in HIV-1-infected
    individuals receiving highly active antiretroviral therapy.** *Blood* 2001,
    97:1898-1901.
17. Shepard BD, Loutfy MR, Raboud J, Mandy F, Kovacs CM, Diong C,
    Bergeron M, Govan V, Rizza SA, Angel JB, Badley AD: **Early changes in T-
    cell activation predict antiretroviral success in salvage therapy of HIV
    infection.** *J Acquir Immune Defic Syndr* 2008, **48**:149-155.
18. Sakai K, Gatanaga H, Takata H, Oka S, Takiguchi M: **Comparison of CD4(+)
    T-cell subset distribution in chronically infected HIV(+) patients with
    various CD4 nadir counts.** *Microbes Infect* 2010, **12**:374-381.
19. Sallusto F, Lanzavecchia A: **Exploring pathways for memory T cell
    generation.** *J Clin Invest* 2001, **108**:805-806.
20. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A: **Two subsets of
    memory T lymphocytes with distinct homing potentials and effector
    functions.** *Nature* 1999, **401**:708-712.
21. Böhler T, Wintergerst U, Linde R, Belohradsky BH, Debatin KM: **CD95 (APO-
    1/Fas) expression on naive CD4(+) T cells increases with disease
    progression in HIV-infected children and adolescents: effect of highly
    active antiretroviral therapy (HAART).** *Pediatr Res* 2001, **49**:101-110.
22. Timmons BW, Bar-Or O: **Lymphocyte expression of CD95 at rest and in
    response to acute exercise in healthy children and adolescents.** *Brain
    Behav Immun* 2007, **21**:442-449.

23. Tuaillon E, Al Tabaa Y, Baillat V, Segondy M, Picot MC, Reynes J, Vendrell JP: **Close association of CD8+/CD38 bright with HIV-1 replication and complex relationship with CD4+ T-cell count.** *Cytometry B Clin Cytom* 2009, **76**:249-260.
24. Onlamoon N, Tabprasit S, Suwanagool S, Louisirirotchanakul S, Ansari AA, Pattanapanyasat K: **Studies on the potential use of CD38 expression as a marker for the efficacy of anti-retroviral therapy in HIV-1-infected patients in Thailand.** *Virology* 2005, **341**:238-247.
25. CDC: **1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.** *MMWR Recomm Rep* 1993, **41**(RR-17):1-19, 1992 Dec 18.
26. Koesters SA, Matu L, Kiama P, Anzala O, Embree J, Plummer FA, Kimani J, Fowke KR: **Elevation of immune activation in kenyan women is associated with alterations in immune function: implications for vaccine development.** *J Clin Immunol* 2004, **24**:702-709.
27. Kassu A, Tsegaye A, Petros B, Wolday D, Hailu E, Tilahun T, Hailu B, Roos MT, Fontanet AL, Hamann D, De Wit TF: **Distribution of lymphocyte subsets in healthy human immunodeficiency virus-negative adult Ethiopians from two geographic locales.** *Clin Diagn Lab Immunol* 2001, **8**:1171-1176.
28. Camara M, Dieye TN, Seydi M, Diallo AA, Fall M, Diaw PA, Sow PS, Mboup S, Kestens L, Jennes W: **Low-level CD4+ T cell activation in HIV-exposed seronegative subjects: influence of gender and condom use.** *J Infect Dis* 2010, **201**:835-842.
29. Collenberg E, Ouedraogo T, Ganame J, Fickenscher H, Kynast-Wolf G, Becher H, Kouyate B, Kräusslich HG, Sangare L, Tebit DM: **Seroprevalence of six different viruses among pregnant women and blood donors in rural and urban Burkina Faso: A comparative analysis.** *J Med Virol* 2006, **78**:683-692.
30. Miles DJ, van der Sande M, Jeffries D, Kaye S, Ismaili J, Ojuola O, Sanneh M, Touray ES, Waight P, Rowland-Jones S, Whittle H, Marchant A: **Cytomegalovirus infection in Gambian infants leads to profound CD8 T-cell differentiation.** *J Virol* 2007, **81**:5766-5776.
31. Mueller YM, De Rosa SC, Hutton JA, Witek J, Roederer M, Altman JD, Katsikis PD: **Increased CD95/Fas-induced apoptosis of HIV-specific CD8(+) T cells.** *Immunity* 2001, **15**:871-882.
32. Paulsen M, Janssen O: **Pro- and anti-apoptotic CD95 signaling in T cells.** *Cell Commun Signal* 2011, **9**:7.
33. Kemp K, Akanmori BD, Hviid L: **West African donors have high percentages of activated cytokine producing T cells that are prone to apoptosis.** *Clin Exp Immunol* 2001, **126**:69-75.
34. Steel A, Cox AE, Shamji MH, John L, Nelson M, Henderson DC, Gotch FM, Gazzard BG, Kelleher P: **HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.** *Antivir Ther* 2007, **12**:971-975.
35. Lenkei R, Bratt G, Holmberg V, Muirhead K, Sandstrom E: **Indicators of T-cell activation: correlation between quantitative CD38 expression and soluble CD8 levels in asymptomatic HIV+ individuals and healthy controls.** *Cytometry* 1998, **33**:115-122.
36. Vollbrecht T, Brackmann H, Henrich N, Roeling J, Seybold U, Bogner JR, Goebel FD, Draenert R: **Impact of changes in antigen level on CD38/PD-1 co-expression on HIV-specific CD8 T cells in chronic, untreated HIV-1 infection.** *J Med Virol* 2010, **82**:358-370.
37. Benito JM, Lopez M, Lozano S, Ballesteros C, Martinez P, Gonzalez-Lahoz J, Soriano V: **Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy.** *J Acquir Immune Defic Syndr* 2005, **38**:373-381.
38. Almeida M, Cordero M, Almeida J, Orfao A: **Relationship between CD38 expression on peripheral blood T-cells and monocytes, and response to antiretroviral therapy: a one-year longitudinal study of a cohort of chronically infected ART-naive HIV-1+ patients.** *Cytometry B Clin Cytom* 2007, **72**:22-33.
39. Amendola A, Poccia F, Martini F, Gioia C, Galati V, Pierdominici M, Marziali M, Pandolfi F, Colizzi V, Piacentini M, Girardi E, D'Offizi G: **Decreased CD95 expression on naive T cells from HIV-infected persons undergoing highly active anti-retroviral therapy (HAART) and the influence of IL-2 low dose administration. Irhan Study Group.** *Clin Exp Immunol* 2000, **120**:324-332.
40. Di Mascio M, Sereti I, Matthews LT, Natarajan V, Adelsberger J, Lempicki R, Yoder C, Jones E, Chow C, Metcalf JA, Sidorov IA, Dimitrov DS, Polis MA, Kovacs JA: **Naive T-cell dynamics in human immunodeficiency virus type 1 infection: effects of highly active antiretroviral therapy provide insights into the mechanisms of naive T-cell depletion.** *J Virol* 2006, **80**:2665-2674.
41. Simpore J, Ilboudo D, Samandoulougou A, Guardo P, Castronovo P, Musumeci S: **HCV and HIV co-infection in pregnant women attending St. Camille Medical Centre in Ouagadougou (Burkina Faso).** *J Med Virol* 2005, **75**:209-212.
42. Ben-Smith A, Gorak-Stolinska P, Floyd S, Weir RE, Lalor MK, Mvula H, Crampin AC, Wallace D, Beverley PC, Fine PE, Dockrell HM: **Differences between naive and memory T cell phenotype in Malawian and UK adolescents: a role for Cytomegalovirus?** *BMC Infect Dis* 2008, **8**:139.
43. Dao B, Nacro B, Dahourou H, Meda N, Van De Perre P: **HIV infection and hepatitis B co-infection: survey of prevalence in pregnant women in Bobo Dioulasso, Burkina Faso.** *Rev Med Brux* 2001, **22**:83-86.
44. Fiasse R, Latinne D: **Intestinal helminths: a clue explaining the low incidence of inflammatory bowel diseases in Subsaharan Africa? Potential benefits and hazards of helminth therapy.** *Acta Gastroenterol Belg* 2006, **69**:418-422.
45. Gopinath R, Ostrowski M, Justement SJ, Fauci AS, Nutman TB: **Filarial infections increase susceptibility to human immunodeficiency virus infection in peripheral blood mononuclear cells in vitro.** *J Infect Dis* 2000, **182**:1804-1808.
46. Kalinkovich A, Weisman Z, Greenberg Z, Nahmias J, Eitan S, Stein M, Bentwich Z: **Decreased CD4 and increased CD8 counts with T cell activation is associated with chronic helminth infection.** *Clin Exp Immunol* 1998, **114**:414-421.